Biomarin Pharmaceutical (BMRN) Total Debt (2010 - 2026)

Biomarin Pharmaceutical (BMRN) has 14 years of Total Debt data on file, last reported at $1.4 billion in Q1 2026.

• Quarterly Total Debt changed N/A year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (changed N/A YoY) and the FY2025 annual result came in at $597.2 million, changed N/A from the prior year.
• Total Debt rose to $1.4 billion in Q1 2026, from $597.2 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $1.4 billion in Q1 2026 to a low of $15.9 million in Q4 2022.
• A 5-year average of $405.4 million and a median of $493.9 million in 2023 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2022 — Total Debt sank 66.98% — and 2023, when it surged 3001.27%.
• Tracing BMRN's Total Debt over 5 years: stood at $15.9 million in 2022, then surged by 3001.27% to $493.9 million in 2023, then increased by 0.19% to $494.8 million in 2024, then advanced by 20.68% to $597.2 million in 2025, then soared by 139.51% to $1.4 billion in 2026.
• The last three Total Debt figures came in at $1.4 billion (Q1 2026), $597.2 million (Q4 2025), and $494.8 million (Q2 2024), per Business Quant data.